124 related articles for article (PubMed ID: 9347245)
1. Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects.
Foot EA; Eastmond R
Diabetes Res Clin Pract; 1997 Oct; 38(1):41-51. PubMed ID: 9347245
[TBL] [Abstract][Full Text] [Related]
2. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
[TBL] [Abstract][Full Text] [Related]
5. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
Antonucci T; Whitcomb R; McLain R; Lockwood D; Norris RM
Diabetes Care; 1997 Feb; 20(2):188-93. PubMed ID: 9118772
[TBL] [Abstract][Full Text] [Related]
6. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
8. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
[TBL] [Abstract][Full Text] [Related]
9. Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus.
Kuzuya T; Kosaka K; Akanuma Y; Shigeta Y; Kaneko T
Diabetes Res Clin Pract; 1998 Aug; 41(2):121-9. PubMed ID: 9789718
[TBL] [Abstract][Full Text] [Related]
10. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Nolan JJ; Ludvik B; Beerdsen P; Joyce M; Olefsky J
N Engl J Med; 1994 Nov; 331(18):1188-93. PubMed ID: 7935656
[TBL] [Abstract][Full Text] [Related]
11. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.
Ebeling P; Teppo AM; Koistinen HA; Viikari J; Rönnemaa T; Nissén M; Bergkulla S; Salmela P; Saltevo J; Koivisto VA
Diabetologia; 1999 Dec; 42(12):1433-8. PubMed ID: 10651262
[TBL] [Abstract][Full Text] [Related]
13. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.
Willi SM; Kennedy A; Brant BP; Wallace P; Rogers NL; Garvey WT
Diabetes Res Clin Pract; 2002 Nov; 58(2):87-96. PubMed ID: 12213349
[TBL] [Abstract][Full Text] [Related]
14. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
15. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA
Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone: an antidiabetic agent.
Chen C
Am J Health Syst Pharm; 1998 May; 55(9):905-25. PubMed ID: 9588250
[TBL] [Abstract][Full Text] [Related]
17. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects.
Suter SL; Nolan JJ; Wallace P; Gumbiner B; Olefsky JM
Diabetes Care; 1992 Feb; 15(2):193-203. PubMed ID: 1547676
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
Horton ES; Whitehouse F; Ghazzi MN; Venable TC; Whitcomb RW
Diabetes Care; 1998 Sep; 21(9):1462-9. PubMed ID: 9727892
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients.
Fonseca V; Foyt HL; Shen K; Whitcomb R
Diabetes Care; 2000 Mar; 23(3):354-9. PubMed ID: 10868865
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone.
Spencer CM; Markham A
Drugs; 1997 Jul; 54(1):89-101; discussion 102. PubMed ID: 9211083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
